CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
Ishani Wickramage,1 Kamani Hemamala Tennekoon,1 Merenchi Arachchige Yasantha Ariyaratne,2 Asanka Sudeshini Hewage,1 Tharmini Sundralingam,1 1Institute of Biochemistry, Molecular Biology and Biotechnology (IBMBB), University of Colombo, Colombo, Sri Lanka; 2National Cancer Institute, Maharagama, Sri...
Guardado en:
Autores principales: | Wickramage I, Tennekoon KH, Ariyaratne MAY, Hewage AS, Sundralingam T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a0a43ca283d402fbdb8713e47f04772 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee W, et al.
Publicado: (2017) -
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee W, et al.
Publicado: (2016) -
Elección del mejor antidepresivo en pacientes con cáncer de mama en tratamiento con tamoxifeno: revisión de la evidencia básica y clínica
por: Irarrázaval O,María Elisa, et al.
Publicado: (2016) -
Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
por: S Khadka, et al.
Publicado: (2016) -
Stability investigations of cytochrome P450 (CYP) enzymes immediately after death in a pig model support the applicability of postmortem hepatic CYP quantification
por: Kata W. Pedersen, et al.
Publicado: (2021)